Experience with degarelix in the treatment of prostate cancer

Therapeutic Advances in Urology

Volumn 5, Issue 1, 2013, Pages 11-24

  Shore, Neal D ^a  

^a Atlantic Urology Clinics   (United States)

Author keywords

degarelix; GnRH agonist; GnRH antagonist; prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; DEGARELIX; FOLLITROPIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; ANTIGEN SPECIFICITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

EID: 84872396685     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212461048     Document Type: Review

References (66)

1. Abrahamsson P. (2010) Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 57: 49–59.
2. Alibhai S. Duong-Hua M. Sutradhar R. Fleshner N. Warde P. Cheung A. (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27: 3452–3458.
3. Ben-Josef E. Yang S. Ji T. Bidart J. Garde S. Chopra D. (1999) Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 161: 970–976.
4. Boccon-Gibod L. van der Meulen E. Persson B. (2011) An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol; 3: 127–140.
5. Broqua P. Riviere P. Conn P. Rivier J. Aubert M. Junien J. (2002) Pharmacological profile of a new, potent, and longacting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 301: 95–102.
6. Crawford E. Tombal B. Miller K. Boccon-Gibod L. Schröder F. Shore N. (2011) A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 186: 889–897.
7. D–Amico A. Chen M. Catalona W. Sun L. Roehl K. Moul J. (2007) Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110: 56–61.
8. Dirnhofer S. Berger C. Hermann M. Steiner G. Madersbacher S. Berger P. (1998) Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 35: 212–220.
9. Doehn C. Sommerauer M. Jocham D. (2006) Drug evaluation: degarelix–a potential new therapy for prostate cancer. IDrugs 9: 565–572.
10. Frampton J. Lyseng-Williamson K. (2009) Degarelix. Drugs 69: 1967–1976.
11. Garde S. Sheth A. Porter A. Pienta K. (1993) Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate 22: 225–233.
12. Gartrell B. Tsao C. Galsky M. (2012) The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies. Urol Oncol 16 April (Epub ahead of print).
13. Gittelman M. Brown T. Holm-Larsen T. Persson B. (2011) Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month phase III clinical trial. UroToday Int J 4(6): art. 81.
14. Gittelman M. Pommerville P. Persson B. Jensen J. Olesen T. on behalf of the Degarelix Study Group (2008) A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 180: 1986–1992.
15. Hanninen M. Venner P. North S. (2009) A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J 3: 369–374.
16. Heidenreich A. Bastian P. Bellmunt J. Bolla M. Joniau S. Masson M. (2012) European Association of Urology. Guidelines on prostate cancer. Available at: http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf (accessed May 2012).
17. Heracek J. Urban M. Sachova J. Kuncova J. Eis V. Mandys V. (2007) The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. Neuro Endocrinol Lett 28: 45–51.
18. Hook W. Karten M. Siraganian R. (1985) Histamine release by structural analogs of LHRH. Fed Am Soc Exp Biol 44: 1323.
19. Huggins C. Hodges C. (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297.
20. Hussain M. Tangen C. Higano C. Schelhammer P. Faulkner J. Crawford E.; Southwest Oncology Group Trial 9346 (INT-0162) (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24: 3984–3990.
21. Hussain M. Tangen C. Higano C. Crawford E. Liu G. Wilding G. (2012) Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. J Clin Oncol 30(Suppl.): abstract 4. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92516 (accessed July 2012).
22. Johansen J. Brasso K. Iversen P. Teisner B. Garnero P. Price P. (2007) Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 13: 3244–3249.
23. Jung K. Lein M. Stephan C. Von Hösslin K. Semjonow A. Sinha P. (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783–791.
24. Keating N. O–Malley A. Freedland S. Smith M. (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102: 39–46.
25. Keating N. O–Malley J. Smith M. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448–4456.
26. Kelly W. Gomella L. (2011) Androgen deprivation therapy and competing risks. JAMA 306: 2382–2383.
27. Klotz L. Boccon-Gibod L. Shore N. Andreou C. Persson B. Cantor P. (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 102: 1531–1538.
28. Koechling W. Hjortkjaer R. Tankó L. (2010) Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol 70: 580–587.
29. Lein M. Wirth M. Miller K. Eickenberg H. Weissbach L. Schmidt K. (2007) Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52: 1381–1387.
30. Levine G. D–Amico A. Berger P. Clark P. Eckel R. Keating N. (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121: 833–840.
31. Lin G. Yao X. Zhang S. Dai B. Ma C. Zhang H. (2009) Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl 11: 443–450.
32. Lipton A. Cook R. Saad F. Major P. Garnero P. Terpos E. (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113: 193–201.
33. Lorente J. Morote J. Raventos C. Encabo G. Valenzuela H. (1996) Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 155: 1348–1351.
34. Mariani S. Salvatori L. Basciani S. Arizzi M. Franco G. Petrangeli E. (2006) Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 175: 2072–2077.
35. Mongiat-Artus P. Teillac P. (2004) Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 5: 2171–2179.
36. Morote J. Orsola A. Planas J. Trilla E. Raventós C. Cecchini L. (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178: 1290–1295.
37. National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®). Prostate cancer. Version 3.2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed May 2012).
38. Oka D. Shiba M. Arai Y. Nakayama M. Takayama H. Inoue H. (2006) Skin reactions to 3-month depot type of luteinizing hormone-releasing hormone agonist therapy. JMAJ 49: 48–54.
39. Ozono S. Ueda T. Hoshi S. Yamaguchi A. Maeda H. Fukuyama Y. (2012) The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol 42: 477–484.
40. Park Y. Hwang I. Jeong C. Kim H. Lee S. Kwak C. (2009) Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. J Urol 181: 2520–2524.
41. Perachino M. Cavalli V. Bravi F. (2010) Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105: 648–651.
42. Pickles T. Tyldesley S. (2011) Testosterone breakthrough during LHRH agonist androgen deprivation with curative radiation: Impact on PSA kinetics and subsequent biochemical outcomes. Eur Urol Suppl 10: 239 (abstract 752).
43. Princivalle M. Broqua P. White R. Meyer J. Mayer G. Elliott L. (2007) Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 320: 1113–1118.
44. Radu A. Pichon C. Camparo P. Antoine M. Allory Y. Couvelard A. (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363: 1621–1630.
45. Ramankulov A. Lein M. Kristiansen G. Loening S. Jung K. (2007) Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67: 330–340.
46. Robinson D. Sandblom G. Johansson R. Garmo H. Stattin P. Mommsen S. (2008) Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 179: 117–122.
47. Sartor O. (2006) Eligard® 6: a new form of treatment for prostate cancer. Eur Urol Suppl 5: 905–910.
48. Schmidt F. Sundaram K. Thau R. Bardin C. (1984) (Ac-D-Dal (2), 4FD-Phe, D-Trp, D-Arg)-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 29: 283–289.
49. Schröder F. Tombal B. Miller K. Boccon-Gibod L. Shore N. Crawford E. (2010) Alkaline phosphatase changes in prostate cancer patients receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study (CS21). BJU Int 106: 182–187.
50. Smith M. Klotz L. Persson B. Olesen T. Wilde A. (2010) Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel-group phase III trial in patients with prostate cancer. J Urol 184: 2313–2319.
51. Smith M. Klotz L. van der Meulen E. Colli E. Tankó L. (2011) Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analyses of prospective clinical trials of degarelix. J Urol 186: 1835–1842.
52. Steinberg M. (2009) Degarelix: a gonadotropin releasing hormone antagonist for the management of prostate cancer. Clin Ther 31: 2312–2331.
53. Stock R. Stone N. (1997) The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 13: 454–460.
54. Thompson I. (2001) Flare associated with LHRH-agonist therapy. Rev Urol 3(Suppl. 3): S10–S14.
55. Tombal B. (2005) Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 4: 14–19.
56. Tombal B. Berges R. (2005) How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 4: 30–36.
57. Tombal B. Berges R. (2008) Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl 7: 15–21.
58. Tombal B. Miller K. Boccon-Gibod L. Schröder F. Shore N. Crawford E. (2010) Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 57: 836–842.
59. US Food and Drug Administration (FDA) (2010) FDA Drug Safety Communication, 20 October. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm (accessed July 2012).
60. Van Poppel H. Klotz L. (2012) Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 19: 594–601.
61. Van Poppel H. Nilsson S. (2008) Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 71: 1001–1006.
62. Van Poppel H. Tombal B. de la Rosette J. Persson B. Jensen J. Olesen T. on behalf of the Degarelix Study Group (2008) Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase II dose-finding study in the treatment of prostate cancer. Eur Urol 54: 805–815.
63. White R. Schwach G. Schteingart C. (2007) Degarelix, a unique, sustained-release depot GnRH blocker with a long duration of action. 1st European Multidisciplinary Meeting on Urological Cancers, Barcelona, 24 November 2007. Abstract P92. Available at: http://www.emucbarcelona2007.org/fileadmin/user_upload/downloads/EMUC_Binnen.pdf (accessed 31 July 2012).
64. Wirth M. Hakenberg O. Froehner M. (2007) Antiandrogens in the treatment of prostate cancer. Eur Urol 51: 306–313.
65. Zhang P. Driscoll D. Lee H. Nolan C. Velagapudi S. (1999) Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody. Hum Pathol 30: 168–172.
66. Zinner N. Bidair M. Centeno A. Tomera K. (2004) Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6mg and 10.8mg: results of a randomized open-label trial. Urology 64: 1177–1181.